General MedicationsORALStandard
TUKYSA
TUCATINIB
Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview TUKYSA is listed in Drugs@FDA under application 213411 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient TUCATINIB Form and strength TABLET;ORAL - 50MG Sponsor SEAGEN Submission history Latest submission status date: 2023-01-19 00:00:00.
Structured Monograph
Clinical summary
Approval overview TUKYSA is listed in Drugs@FDA under application 213411 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient TUCATINIB Form and strength TABLET;ORAL - 50MG Sponsor SEAGEN Submission history Latest submission status date: 2023-01-19 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.